ODI Pharma AB: Publication of interim report Q3 2023/2024
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2023 - March 2024. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.Third quarter (2024-01-01 – 2024-03-31)The Group's net sales amounted to SEK 13,856,539 (10,801).The Group's profit after financial items amounted to SEK 1,389,713 (-942,440).Result per share amounted to SEK 0,09 (-0.06).* Nine months (2023-07-01 – 2024-03-31)The Group’s net sales amounted to SEK 14,777,194 (112,